PTAB challenges

Based on the provided information and further research into the PTAB trial history, here is an analysis of the proceedings involving US patent 11,021,437.

Proceedings overview

One AIA trial proceeding, an Inter Partes Review (IPR), has been filed against US patent 11,021,437. The Patent Trial and Appeal Board (PTAB) exercised its discretion to deny the institution of this trial, meaning no claims were reviewed on the merits and all claims remain valid. This outcome strengthens the patent's standing, though the denial's discretionary nature means the underlying invalidity arguments were not adjudicated and could potentially be raised again.

---

IPR2025-00874 — Aquestive Therapeutics, Inc. v. Iono Pharma LLC

• Type: Inter Partes Review
• Filed: 2025-05-16
• Status: Discretionary Denial. This means the PTAB declined to institute a trial, not on the merits of the prior art challenge, but based on procedural or discretionary factors. The patent claims were not reviewed.
• Judge panel: I am unable to locate the specific judge panel for this decision with high confidence. This information is typically available on the first page of the Institution Decision document.
• Petition grounds: I do not have access to the specific claims challenged or the prior art asserted in the petition. This would be detailed in the petition document filed with the PTAB. Generally, IPRs are based on grounds of anticipation (§ 102) or obviousness (§ 103) over prior art consisting of patents or printed publications.
• Institution decision: The PTAB denied institution on 2026-02-24. A discretionary denial often occurs when there is parallel litigation in a district court that is nearing a final resolution, and the Board decides that allowing the IPR to proceed would be an inefficient use of resources (a Fintiv denial). The Board did not opine on the merits of the petitioner's invalidity arguments.
• Final Written Decision: None was issued because the trial was not instituted.
• Settlement / termination: The proceeding was terminated at the institution phase by the PTAB's denial; it did not proceed to a point where a settlement would terminate the trial itself.
• Appeal: A decision to deny institution of an IPR is generally not appealable to the U.S. Court of Appeals for the Federal Circuit.
• Defensive value: This proceeding offers limited defensive value. While it shows the patent has faced a challenge, the denial was not based on the strength of the patent. Because it was a discretionary denial, the petitioner (Aquestive Therapeutics) is not statutorily estopped from raising the same invalidity arguments again, either in a future IPR or in district court litigation. This means the prior art and arguments raised in the petition remain a potential threat.

Strategic summary

All claims of US patent 11,021,437 remain valid, patentable, and untested on the merits before the PTAB. The single IPR filed against it, IPR2025-00874, was denied institution on discretionary grounds, not because the invalidity arguments were found to be weak.

Crucially, this discretionary denial means that the estoppel provisions of 35 U.S.C. § 315(e) do not apply. The petitioner, Aquestive Therapeutics, Inc., (and any real parties-in-interest or their privies) is free to raise the very same invalidity arguments from its petition in a subsequent PTAB filing or in district court. For another defendant, this means that all prior-art grounds remain available. The arguments Aquestive assembled are likely well-researched and could provide a roadmap for a future invalidity defense.

The petitioner, Aquestive Therapeutics, is listed in the patent's file history as an applicant citing this patent family in its own patent applications, suggesting they are a direct competitor in the sublingual and buccal drug delivery space. This IPR was likely a strategic maneuver related to market competition or concurrent litigation. The denial preserves the status quo, leaving the patent's validity as an open question to be resolved in court or a future PTAB proceeding.

Recommended next steps

For a defendant currently facing an assertion of US patent 11,021,437:

• Obtain the IPR Petition: The first and most critical step is to acquire the full petition and exhibits filed in IPR2025-00874 from the USPTO's PTAB E2E portal. This will reveal the specific claims challenged, the prior art references Aquestive relied upon, and the detailed expert arguments for why the claims are allegedly invalid. These arguments are not estopped and are available for your use.
• Analyze the Discretionary Denial: Review the PTAB's Decision Denying Institution to understand the specific reasons for the denial (e.g., advanced state of parallel litigation). This context is important for assessing whether a new IPR filed by a different party would face a similar fate.
• Evaluate the Untested Grounds: Use the prior art and arguments from the Aquestive petition as a starting point for your own invalidity analysis. Since the PTAB never ruled on the merits, these grounds remain potent and have been conveniently packaged by a motivated competitor.